Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26+ cancer stem cells in colorectal carcinoma

[1] Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[2] Bray F(2007)Actual 10-year survival after resection of colorectal liver metastases defines cure J Clin Oncol 25 4575-80

[3] Center MM(1997)Liver resection for colorectal metastases J Clin Oncol 15 938-46

[4] Ferlay J(2004)Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases Ann Surg 239 818-25

[5] Ward E(2008)A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation Br J Cancer 98 71-6

[6] Forman D(2010)A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer Cell Stem Cell 6 603-15

[7] Tomlinson JS(2009)Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway Recent Pat Anticancer Drug Discov 4 28-35

[8] Jarnagin WR(2008)Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy Clin Cancer Res 14 342-6

[9] DeMatteo RP(2013)B-Raf and the inhibitors: from bench to bedside J Hematol Oncol 6 30-98

[10] Fong Y(2012)RAF265 inhibits the growth of advanced human melanoma tumors Clin Cancer Res 18 2184-85

[1] Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[2] Bray F(2007)Actual 10-year survival after resection of colorectal liver metastases defines cure J Clin Oncol 25 4575-80

[3] Center MM(1997)Liver resection for colorectal metastases J Clin Oncol 15 938-46

[4] Ferlay J(2004)Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases Ann Surg 239 818-25

[5] Ward E(2008)A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation Br J Cancer 98 71-6

[6] Forman D(2010)A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer Cell Stem Cell 6 603-15

[7] Tomlinson JS(2009)Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway Recent Pat Anticancer Drug Discov 4 28-35

[8] Jarnagin WR(2008)Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy Clin Cancer Res 14 342-6

[9] DeMatteo RP(2013)B-Raf and the inhibitors: from bench to bedside J Hematol Oncol 6 30-98

[10] Fong Y(2012)RAF265 inhibits the growth of advanced human melanoma tumors Clin Cancer Res 18 2184-85